Incidence of WHO Stage 3 and 4 Conditions following Initiation of Anti-Retroviral Therapy in Resource Limited Settings

• Andrea J. Curtis,

  Affiliation Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia

  ⨯
• Catherine S. Marshall,

  Affiliation Infectious Diseases Unit, Alfred Hospital, Melbourne, Australia

  ⨯
• Tim Spelman,

  Affiliations Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia, Centre for Population Health, Burnet Institute, Melbourne, Australia

  ⨯
• Jane Greig,

  Affiliation Manson Unit, Médecins Sans Frontières, London, United Kingdom

  ⨯
• Julian H. Elliot,

  Affiliations Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia, Infectious Diseases Unit, Alfred Hospital, Melbourne, Australia, Centre for Population Health, Burnet Institute, Melbourne, Australia

  ⨯
• Leslie Shanks,

  Affiliation Public Health Department, Médecins Sans Frontières, Amsterdam, The Netherlands

  ⨯
• Philipp Du Cros,

  Affiliation Manson Unit, Médecins Sans Frontières, London, United Kingdom

  ⨯
• Esther C. Casas,

  Affiliation Public Health Department, Médecins Sans Frontières, Amsterdam, The Netherlands

  ⨯
• Marcio Silveria Da Fonseca,

  Affiliation Public Health Department, Médecins Sans Frontières, Amsterdam, The Netherlands

  ⨯
• Daniel P. O’Brien

  * E-mail: daniel.obrien@amsterdam.msf.org

  Affiliations Manson Unit, Médecins Sans Frontières, London, United Kingdom, Department of Infectious Diseases, Geelong Hospital, Geelong, Australia, Department of Medicine and Infectious Diseases, Royal Melbourne Hospital, University of Melbourne, Melbourne, Australia

  ⨯